Residency · Residency · Respirology

Diffusion Capacity and Gas Exchange Physiology

Physiology of Gas Exchange

Oxygen Transport Fundamentals

Gas exchange in the human lung occurs across the alveolocapillary membrane, an extraordinarily thin barrier measuring only 0.2 to 0.5 micrometers in thickness, yet spanning an enormous surface area of approximately 70 square meters. This elegant architecture reflects the evolutionary optimization of the lung for efficient gas transfer. The rate of gas diffusion across this membrane is governed by Fick's law, which states that the volume of gas transferred (V_gas) is proportional to the surface area (A) multiplied by the diffusion coefficient of the gas (D) multiplied by the partial pressure gradient (P1 - P2), divided by the membrane thickness (T). Each of these variables has direct clinical relevance: diseases that reduce surface area (emphysema), thicken the membrane (fibrosis), or diminish the driving pressure gradient all impair gas exchange. Carbon dioxide diffuses approximately 20 times faster than oxygen despite similar molecular weights, owing to its substantially higher solubility in tissue. This explains why CO2 retention is a relatively late finding in diffusion-limited disease and why hypoxemia typically precedes hypercapnia.

The transit time of a red blood cell through the pulmonary capillary is approximately 0.75 seconds at rest, and oxygen equilibration between alveolar gas and pulmonary capillary blood is normally complete within the first 0.25 seconds of transit. This provides a substantial diffusion reserve, meaning that under resting conditions, there is approximately three times more capillary transit time than is needed for complete equilibration. This reserve becomes clinically relevant during exercise, when increased cardiac output shortens capillary transit time to as little as 0.25 seconds, and at altitude, when a reduced alveolar PO2 narrows the driving pressure gradient. In these settings, diseases that impair diffusion, such as interstitial fibrosis or emphysema, may manifest as exercise-induced desaturation even when resting oxygenation is preserved.

Alveolar Gas Equation

The alveolar gas equation is fundamental to understanding the mechanisms of hypoxemia. It is expressed as PAO2 = FiO2 x (Patm - PH2O) - (PaCO2 / R), where R is the respiratory quotient, which approximates 0.8 on a typical Western diet. At sea level on room air, this equation yields a predicted alveolar PO2 of approximately 100 mmHg: 0.21 x (760 - 47) - (40 / 0.8). The alveolar-arterial (A-a) gradient, calculated as PAO2 minus PaO2, quantifies the efficiency of gas exchange across the alveolocapillary membrane. The normal A-a gradient can be estimated by the formula (age/4) + 4, or approximately 2.5 + (0.21 x age), and typically ranges from 5 to 15 mmHg in healthy young adults. An elevated A-a gradient narrows the differential diagnosis of hypoxemia to three mechanisms: ventilation-perfusion (V/Q) mismatch, shunt, and diffusion impairment. Conversely, a normal A-a gradient in the setting of hypoxemia limits the differential to hypoventilation and low inspired FiO2 (as encountered at altitude), both of which impair oxygenation through reductions in alveolar PO2 rather than through abnormalities in gas exchange.

Causes of Hypoxemia - The Five Mechanisms

A systematic understanding of the five mechanisms of hypoxemia is essential for clinical reasoning. Ventilation-perfusion (V/Q) mismatch is the most common mechanism, occurring when regions of lung receive inadequate ventilation relative to their perfusion, or vice versa. This is the predominant mechanism in COPD, asthma, and pulmonary embolism, and it is characteristically responsive to supplemental oxygen, which raises the alveolar PO2 in poorly ventilated but perfused units. Shunt refers to the passage of blood through the pulmonary vasculature without participating in gas exchange, either through intracardiac defects (atrial septal defect, ventricular septal defect, patent foramen ovale) or through intrapulmonary channels (arteriovenous malformations, hepatopulmonary syndrome, or completely collapsed/consolidated alveoli as in ARDS). Shunt physiology is distinguished by its relative refractoriness to supplemental oxygen; when the shunt fraction exceeds approximately 30%, even high concentrations of inspired oxygen fail to significantly improve PaO2. Diffusion impairment is rarely the sole cause of hypoxemia at rest but becomes clinically significant during exercise, when shortened capillary transit time exposes the inadequacy of a thickened or damaged alveolocapillary membrane, as occurs in interstitial lung disease and emphysema. Hypoventilation produces hypoxemia through a direct reduction in alveolar PO2, with PaCO2 rising proportionally as PaO2 falls; the A-a gradient remains normal because the gas exchange apparatus itself is intact. Low inspired FiO2, as encountered at altitude, similarly reduces alveolar PO2 while the A-a gradient remains normal.

<image>A detailed physiological diagram of the alveolocapillary unit showing oxygen and carbon dioxide diffusion across the membrane. Label the alveolar epithelium (Type I and Type II pneumocytes), basement membrane, capillary endothelium, plasma layer, and red blood cell. Show partial pressure gradients with numerical values: alveolar PO2 = 100 mmHg, mixed venous PO2 = 40 mmHg, with equilibration curve along the capillary length. Include a graph inset showing PO2 vs. capillary transit time under normal conditions, exercise, and fibrosis/thickened membrane conditions.</image>

DLCO: Measurement and Technique

Principles of DLCO Measurement

The diffusing capacity of the lung for carbon monoxide (DLCO), referred to as TLCO in European nomenclature, provides a clinical measure of the lung's capacity to transfer gas from the alveolar space into the pulmonary capillary blood. Carbon monoxide was chosen as the test gas for three key reasons: first, CO has an exceptionally high affinity for hemoglobin (approximately 210 times that of oxygen), ensuring that virtually all CO molecules that cross the alveolocapillary membrane are immediately bound by hemoglobin; second, this high affinity means that the back-pressure of CO in the pulmonary capillary blood is negligible, maintaining a maximal driving pressure gradient throughout the measurement; and third, CO transfer is diffusion-limited rather than perfusion-limited, meaning that the rate of uptake reflects the properties of the membrane and the hemoglobin available for binding, rather than simply the rate of blood flow. The DLCO can be mathematically decomposed as the product of alveolar volume (VA) and the transfer coefficient (KCO, or DLCO/VA). The most widely used measurement technique is the single-breath method, in which the patient inspires a gas mixture containing 0.3% CO and an inert tracer gas (helium, methane, or neon), holds the breath for 10 seconds, and then exhales. The rate of CO disappearance from the inspired gas is used to calculate the DLCO.

Technical Standards (ATS/ERS 2017)

Adherence to technical standards is critical for generating reliable DLCO measurements. The inspired volume must be at least 85% of the patient's largest known vital capacity to ensure adequate filling of the alveolar compartment. Breath-hold time is standardized at 10 plus or minus 2 seconds, measured using the Jones-Meade method, which accounts for the time from the beginning of inspiration to the midpoint of sample collection. After the breath-hold, the washout volume of 750 to 1000 mL clears the dead space gas, and the subsequent sample collection volume of 500 to 1000 mL represents the alveolar gas for analysis. A minimum of 4 minutes between tests prevents carryover of CO from depleting binding sites, and the results of two acceptable tests should agree within 2 mL/min/mmHg. Appropriate corrections for body temperature and pressure (BTPS for volumes, STPD for gas concentrations) must be applied, and hemoglobin adjustment is mandatory before reporting the final DLCO value.

Hemoglobin Adjustment

Because CO binds directly to hemoglobin, the DLCO is directly influenced by the amount of hemoglobin available in the pulmonary capillaries. The standard correction formula for males is: adjusted DLCO = measured DLCO x (1.7 x Hb / (10.22 + Hb)), and for females: adjusted DLCO = measured DLCO x (1.7 x Hb / (9.38 + Hb)). Anemia causes a spuriously low DLCO by reducing the number of hemoglobin binding sites available for CO uptake, while polycythemia produces a spuriously elevated DLCO through the opposite mechanism. The clinical implication is clear: the DLCO should always be corrected for hemoglobin before interpretation, and failure to do so is the most common source of misinterpretation in pulmonary function laboratories.

Adjustment for Carboxyhemoglobin and Altitude

Elevated carboxyhemoglobin (COHb) levels reduce the measured DLCO by occupying hemoglobin binding sites that would otherwise be available for test CO uptake, effectively reducing the driving pressure gradient. COHb levels above 2% produce measurable effects. Smokers commonly have COHb levels between 5% and 15%, which can significantly depress the DLCO, and patients should be instructed to abstain from smoking for at least 24 hours before testing. Altitude also affects DLCO measurement, with values increasing by approximately 2 to 3% per 1000 feet above sea level, owing to the lower ambient partial pressure of CO, which reduces back-pressure and increases the effective driving gradient.

DLCO Interpretation

Causes of Decreased DLCO

A reduced DLCO can result from destruction of the alveolocapillary membrane, thickening of the membrane, reduction in pulmonary capillary blood volume, or a decrease in hemoglobin available for CO binding. In emphysema, destruction of alveolar walls reduces the surface area for gas exchange, making a low DLCO the hallmark pulmonary function finding that distinguishes emphysema from chronic bronchitis (where DLCO is typically preserved). In interstitial lung disease, including idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, and asbestosis, the alveolocapillary membrane is thickened by fibrosis, increasing the diffusion path length. Pulmonary vascular disease, encompassing pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and vasculitis, reduces the pulmonary capillary blood volume available for gas exchange. Anemia reduces the hemoglobin available for CO binding and must always be corrected for before interpreting a low DLCO. Prior pneumonectomy or lobectomy reduces the total surface area proportionally to the volume of lung removed. Pulmonary edema can paradoxically increase or decrease the DLCO depending on the stage: early interstitial edema may increase DLCO by expanding pulmonary blood volume, while alveolar flooding eventually impairs gas transfer.

Causes of Increased DLCO

An elevated DLCO has a focused differential diagnosis and is clinically valuable in specific scenarios. Alveolar hemorrhage is the most important cause: free hemoglobin present in the alveolar space absorbs CO during the breath-hold, producing a spuriously elevated DLCO. A DLCO exceeding 140% of predicted is considered classic for diffuse alveolar hemorrhage and, in the appropriate clinical context (hemoptysis, declining hemoglobin, ground glass opacities on CT), is virtually diagnostic of conditions such as Goodpasture disease, granulomatosis with polyangiitis, or microscopic polyangiitis. Polycythemia increases the DLCO through the provision of additional hemoglobin binding sites. Left-to-right intracardiac shunts, particularly in early atrial septal defect, increase pulmonary blood flow and capillary blood volume. Asthma may produce a mildly elevated DLCO due to air trapping increasing the residual blood volume exposure. Obesity increases pulmonary blood volume, and recent exercise augments pulmonary capillary recruitment.

KCO (DLCO/VA) - The Transfer Coefficient

The transfer coefficient, KCO, is calculated as the ratio of DLCO to alveolar volume and is frequently misunderstood in clinical practice. It is emphatically not simply a "corrected DLCO." The KCO increases when the alveolar volume is disproportionately reduced relative to the DLCO, as occurs after pneumonectomy, during submaximal inspiration (insufficient inspired volume during the test), or in extraparenchymal restriction from chest wall disease. In these settings, the remaining lung tissue is intrinsically normal, and the concentration of CO uptake per unit volume of ventilated lung is preserved or even increased because the pulmonary capillary blood volume is compressed into a smaller aerated lung volume. Conversely, the KCO decreases when there is true parenchymal disease that impairs gas transfer per unit of lung tissue, as in emphysema, interstitial lung disease, and pulmonary vascular disease. The primary clinical utility of KCO lies in distinguishing extraparenchymal causes of restriction (where KCO is normal or elevated) from intrinsic parenchymal disease (where KCO is reduced).

<image>A clinical interpretation table presented as a color-coded matrix showing DLCO and KCO patterns across different disease states. Rows: emphysema, ILD (pulmonary fibrosis), pulmonary vascular disease, neuromuscular disease, pneumonectomy, alveolar hemorrhage, anemia. Columns: DLCO (high/normal/low), KCO (high/normal/low), VA (high/normal/low). Use red for decreased, green for increased, yellow for normal. Include a brief clinical explanation for each pattern.</image>

Ventilation-Perfusion Relationships

V/Q Ratio Concepts

The efficiency of gas exchange depends upon the matching of ventilation to perfusion throughout the lung. The ideal V/Q ratio is approximately 0.8, reflecting a normal alveolar ventilation of about 4 L/min matched to a cardiac output of approximately 5 L/min. In reality, the V/Q ratio is not uniform but varies considerably from the apex to the base of the upright lung, driven primarily by the gravitational effects on pulmonary blood flow. At the apex, where blood flow is lowest and ventilation is relatively preserved, the V/Q ratio is high (approximately 3.0, corresponding to West Zone 1), and alveoli are relatively overventilated relative to perfusion. At the base, where blood flow is greatest, the V/Q ratio is lower (approximately 0.6, corresponding to West Zone 3). Dead space ventilation represents the extreme of high V/Q, where ventilation occurs without any perfusion (V/Q approaches infinity), while shunt represents the opposite extreme, where perfusion occurs without ventilation (V/Q equals zero). The West zones of the lung describe the relationship between alveolar pressure (PA), arterial pressure (Pa), and venous pressure (Pv): Zone 1 (PA > Pa > Pv), Zone 2 (Pa > PA > Pv), and Zone 3 (Pa > Pv > PA).

Quantifying V/Q Mismatch

Several methods allow quantification of the degree of V/Q abnormality. Physiologic dead space is estimated using the Bohr equation: VD/VT = (PaCO2 - PECO2) / PaCO2, where PECO2 is the mixed expired CO2 pressure. The normal dead space fraction is approximately 0.3 at rest, meaning about one-third of each tidal breath ventilates non-gas-exchanging dead space. The shunt fraction is quantified by the shunt equation: Qs/Qt = (CcO2 - CaO2) / (CcO2 - CvO2), which requires measurement of the oxygen content in end-capillary, arterial, and mixed venous blood. A clinical approximation is provided by the 100% oxygen shunt study: if PaO2 fails to rise above 500 mmHg when the patient breathes 100% FiO2, a significant shunt is present. As a general rule, each 5% increment in shunt fraction reduces PaO2 by approximately 20 to 25 mmHg on room air.

Clinical Applications of ABG Interpretation

Arterial blood gas analysis provides essential information for classifying respiratory failure and guiding management. Type 1 respiratory failure is defined as a PaO2 below 60 mmHg with a normal or low PaCO2, indicating a primary oxygenation defect without ventilatory compromise. Type 2 respiratory failure is defined as a PaO2 below 60 mmHg combined with a PaCO2 above 45 mmHg, indicating concurrent ventilatory failure. The distinction between acute and chronic CO2 retention is made by examining the degree of metabolic compensation: for each 10 mmHg rise in PaCO2, the bicarbonate rises by approximately 1 mEq/L in the acute setting (reflecting buffering alone) versus 3.5 mEq/L in the chronic setting (reflecting renal compensation). The P/F ratio (PaO2 divided by FiO2) provides a standardized measure of oxygenation efficiency. The Berlin definition of ARDS uses P/F thresholds of less than 300 (mild), less than 200 (moderate), and less than 100 (severe) to stratify disease severity and guide management decisions.

<image>A three-dimensional representation of the V/Q ratio distribution in the lung, showing a bell-shaped curve centered around V/Q = 1.0 for a normal lung. Overlay a second curve showing a bimodal distribution typical of COPD (with peaks at low V/Q near 0.1 and high V/Q near 10). Include a third overlay showing a pure shunt (spike at V/Q = 0). Label x-axis as V/Q ratio (log scale from 0 to 100), y-axis as blood flow or ventilation (L/min). Use different colors for each curve with a legend. Include anatomical insets showing West zones 1, 2, and 3 in an upright lung with pressure relationships labeled.</image>

Exercise Gas Exchange

Cardiopulmonary Exercise Testing (CPET) and DLCO

The integration of DLCO with exercise testing provides valuable insight into the functional limitations of patients with pulmonary disease. Exercise-induced desaturation in the setting of a low resting DLCO is a hallmark of pulmonary vascular limitation or interstitial lung disease, reflecting the failure of gas exchange to keep pace with the increased metabolic demands of exercise. A DLCO below 40% predicted is associated with significant exercise limitation and a high likelihood of exertional desaturation. The six-minute walk test (6MWT) provides a practical surrogate for formal CPET: a desaturation of more than 4% or a nadir SpO2 below 88% is considered clinically significant and has prognostic implications in IPF, COPD, and pulmonary hypertension. Full cardiopulmonary exercise testing with metabolic gas analysis can differentiate among cardiac, pulmonary, deconditioning, and peripheral vascular causes of exercise limitation, providing information that no resting test can replicate.

Prognostic Value of DLCO

The DLCO carries significant prognostic information across multiple disease states. In IPF, a DLCO below 40% predicted is one of the criteria for referral for lung transplantation evaluation, and a decline of more than 15% over 6 to 12 months suggests progressive disease with substantially increased mortality risk. In COPD, a DLCO below 60% predicted correlates with the severity of emphysema on CT and with increased mortality risk; the DLCO also contributes indirectly to the BODE prognostic index through its correlation with FEV1 and exercise capacity. In pulmonary arterial hypertension, an isolated low DLCO with preserved spirometry and lung volumes is a classic early finding that should trigger further evaluation with echocardiography and right heart catheterization. In systemic sclerosis, annual DLCO screening is recommended because a decline in DLCO frequently precedes the clinical development of both interstitial lung disease and pulmonary hypertension, allowing earlier intervention.

Key Clinical Pearls

• A low DLCO with preserved spirometry should always prompt consideration of pulmonary vascular disease (PAH, CTEPH) or early ILD
• KCO is often misinterpreted as "corrected DLCO" - it is most useful for distinguishing parenchymal from extraparenchymal causes of restriction
• An elevated DLCO > 140% predicted in the right clinical context (hemoptysis, dropping hemoglobin, ground glass on CT) is virtually diagnostic of diffuse alveolar hemorrhage
• Always correct DLCO for hemoglobin before interpretation; failure to do so is the most common source of misinterpretation
• A normal A-a gradient in a hypoxemic patient narrows the differential to hypoventilation or altitude

References

1. Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):1600016.
2. Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186(2):132-139.
3. West JB, Luks AM. West's Respiratory Physiology: The Essentials. 11th ed. Wolters Kluwer; 2021.
4. Neder JA, Berton DC, Muller PT, et al. Incorporating DLCO and KCO into clinical decision making. Respir Med. 2021;176:106242.
5. Johnson DC. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. Respir Med. 2000;94(1):28-37.

Read this lecture as Markdown